Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Inclusion Criteria: * Japanese men and women ≥ 50 years of age * Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD, including juxta-foveal lesions that affect the fovea as evidenced by fluorescein angiography (FA) in the study eye * Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) of 73 to 25 letters (approximately 20/40 to 20/320 at Snellen equivalent) in the study eye Exclusion Criteria: * Prior treatment of the study eye with intraocular anti-VEGF(Vascular Endothelial Growth Factor) agents, verteporfin photodynamic therapy (PDT), other laser, intraocular corticosteroids, surgical interventions (except cataract surgery more than 30 days prior to screening) or systemic use of anti-VEGF products within 3 months prior to study entry * Active or suspected infection in or surrounding of the study eye * Active severe intraocular inflammation in the study eye * Intraocular pressure (IOP) ≥ 25 mmHg in the study eye * Ocular condition in the study eye which may impact vision and confound study outcomes